Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today...
clinical trials
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, (NRx), a clinical-stage biopharmaceutical company and Nephron Pharmaceuticals, Inc. (Nephron), a...
On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D...
GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of “GC1109”, an anthrax vaccine...
VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the...
RoadMap Technologies, a leading provider of data science and software solutions for the Life Sciences industry, today...
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company today announced further alignment with...
Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now...
BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as “BioRay”) announced on October 7th that its clinical trial application for...
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
2 min read
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the submission of a New Drug Application (NDA) to the U.S. Food and...